Universität zu Köln

Tahmaz, Volkan, Gehlsen, Uta ORCID: 0000-0001-9057-9199, Sauerbier, Laura, Holtick, Udo, Engel, Lisa, Radojska, Stela, Petrescu-Jipa, Viorica-Maria, Scheid, Christof, Hallek, Michael, Gathof, Birgit, Cursiefen, Claus and Steven, Philipp (2017). Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort study. Br. J. Ophthalmol., 101 (3). S. 322 - 327. LONDON: BMJ PUBLISHING GROUP. ISSN 1468-2079

Full text not available from this repository.

Abstract

Background/Aims To analyse patients with chronic ocular graft-versus-host disease (GvHD) under treatment with 100% autologous serum eye drops from a sealed manufacturing system. Methods 17 patients with chronic ocular GvHD received 100% autologous serum eye drops from single use vials manufactured in a sealed system. Retrospective analysis included visual acuity, corneal staining, frequency of artificial tears, ocular symptoms by means of a questionnaire and information on subjective side effects and cost compensation. Results Data of prior to autologous serum eye drops therapy and at a 6-month follow-up were obtained. They demonstrated a significant increase in visual acuity (logMAR oculus dexter/right eye (OD) 0.50.32 to 0.4 +/- 0.3; oculus sinister/left eye (OS) 0.6 +/- 0.35 to 0.3 +/- 0.35; p=0.177/0.003) and significant improvement in corneal staining (Oxford grading scheme: OD from 3 +/- 1.03 to 2 +/- 1.43, OS from 4 +/- 1.0 to 2 +/- 1.09, p=0.004/0.001) and ocular symptoms (ocular surface disease index: 88 +/- 20.59 to 63 +/- 22.77; p=0.02). Frequency of artificial tears was reduced and no side effects were reported. Patient satisfaction was 100%, and cost compensation by health insurance reached 80%. Conclusions 100% autologous serum eye drops using a sealed manufacturing system were efficient in improving the ocular surface, patient symptoms and visual acuity without side effects. It seems to be safe to use 100% autologous serum despite earlier suspicions regarding immune complex accumulations and exacerbation of ocular surface inflammation. The potential effects of serum levels of systemic immunosuppressives through readministration onto the ocular surface need to be elucidated.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Tahmaz, Volkan UNSPECIFIED UNSPECIFIED UNSPECIFIED Gehlsen, Uta UNSPECIFIED orcid.org/0000-0001-9057-9199 UNSPECIFIED Sauerbier, Laura UNSPECIFIED UNSPECIFIED UNSPECIFIED Holtick, Udo UNSPECIFIED UNSPECIFIED UNSPECIFIED Engel, Lisa UNSPECIFIED UNSPECIFIED UNSPECIFIED Radojska, Stela UNSPECIFIED UNSPECIFIED UNSPECIFIED Petrescu-Jipa, Viorica-Maria UNSPECIFIED UNSPECIFIED UNSPECIFIED Scheid, Christof UNSPECIFIED UNSPECIFIED UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Gathof, Birgit UNSPECIFIED UNSPECIFIED UNSPECIFIED Cursiefen, Claus UNSPECIFIED UNSPECIFIED UNSPECIFIED Steven, Philipp UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-238820
DOI:	10.1136/bjophthalmol-2015-307666
Journal or Publication Title:	Br. J. Ophthalmol.
Volume:	101
Number:	3
Page Range:	S. 322 - 327
Date:	2017
Publisher:	BMJ PUBLISHING GROUP
Place of Publication:	LONDON
ISSN:	1468-2079
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language SEVERE DRY EYE; EPITHELIAL DEFECTS; IN-VITRO; CORNEAL; DIAGNOSIS; BLOOD; MANAGEMENT; GVHD Multiple languages Ophthalmology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/23882